The impact of dialysis type on biomarkers for cardiovascular diseases

Turk Kardiyoloji Dernegi Arsivi

Volumn 39, Issue 6, 2011, Pages 456-462

  Şahinarslan, Asife ^a   Güz, Galip ^a   Mutluay, Rüya ^a   Okyay, Kaan ^a   Demirtaş, Canan ^a   Paşaoǧlu, Hatice ^a   Yalçin, Ridvan ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

Biological markers; Cardiovascular diseases; Dialysis adverse effects; Kidney failure, chronic complications

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN PRECURSOR;

ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; ADULT; BLOOD; CHRONIC KIDNEY FAILURE; CLASSIFICATION; HOSPITALIZATION; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; TROPONIN I; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855178603     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2011.01289     Document Type: Article

References (25)

1. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853-906. (Pubitemid 28516321)
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-9. (Pubitemid 28527268)
3. Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P, et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30:334-42. (Pubitemid 27391500)
4. Vonesh EF, Moran J. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1999;10:354-65. (Pubitemid 29068076)
5. Roberts MA, Srivastava PM, Macmillan N, Hare DL, Ratnaike S, Sikaris K, et al. B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol 2008;3:1057-65.
6. Gutiérrez OM, Tamez H, Bhan I, Zazra J, Tonelli M, Wolf M, et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem 2008;54:1339-48.
7. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002;80:103-8.
8. Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997;94:8093-8. (Pubitemid 27343782)
9. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16. (Pubitemid 351679597)
10. Lucia P, Coppola A, Manetti LL, Sebastiani ML, Colliardo A, Cerroni F, et al. Cardiac troponin I in acute coronary ischemic syndromes. Epidemiological and clinical correlates. Int J Cardiol 2001;77:215-22. (Pubitemid 32155907)
11. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004;50:2279-85. (Pubitemid 39552162)
12. Danesh J, Collins R, Peto R, Lowe GD. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000;21:515-20. (Pubitemid 30148316)
13. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-809.
14. Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, et al. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J 2003;145:467-74. (Pubitemid 36390493)
15. Held PJ, Port FK, Turenne MN, Gaylin DS, Hamburger RJ, Wolfe RA. Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions. Kidney Int 1994;45:1163-9. (Pubitemid 24234735)
16. Foley RN, Parfrey PS, Harnett JD, Kent GM, O'Dea R, Murray DC, et al. Mode of dialysis therapy and mortality in end-stage renal disease. J Am Soc Nephrol 1998;9:267-76. (Pubitemid 28092075)
17. Zoccali C, Mallamaci F, Tripepi G. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif 2003;21:29-36. (Pubitemid 36173345)
18. Samouilidou EC, Grapsa EJ, Kakavas I, Lagouranis A, Agrogiannis B. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. IntUrol Nephrol 2003;35:393-7. (Pubitemid 39127558)
19. Yilmaz FM, Akay H, Duranay M, Yilmaz G, Öztekin PS, Koşar U, et al. Carotid atherosclerosis and cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Clin Biochem 2007;40:1361-6. (Pubitemid 350151422)
20. Tonbul HZ, Demir M, Altintepe L, Güney İ, Yeter E, Türk S, et al. Malnutrition-inflammation-atherosclerosis (MIA) syndrome components in hemodialysis and peritoneal dialysis patients. Ren Fail 2006;28:287-94. (Pubitemid 43977338)
21. Paniagua R, Ventura MD, Avila-Díaz M, Hinojosa- Heredia H, Méndez-Durán A, Cueto-Manzano A, et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant 2010;25:551-7.
22. Svensson M, Gorst-Rasmussen A, Schmidt EB, Jorgensen KA, Christensen JH. NT-pro-BNP is an independent predictor of mortality in patients with end-stage renal disease. Clin Nephrol 2009;71:380-6.
23. Kanwar M, Hashem M, Rosman H, Kamalakannan D, Cheema A, Ali A, et al. Usefulness of clinical evaluation, troponins, and C-reactive protein in predicting mortality among stable hemodialysis patients. Am J Cardiol 2006; 98:1283-7. (Pubitemid 44739920)
24. Sutidze M, Kajrishvili M, Tsimakuridze M, Khachapuridze N, Sulakvelidze M. Factors associated with increased serum levels of specific markers of myocardial injury-cardiac troponins T and I in chronic haemodialysis patients. Georgian Med News 2009;169:39-43.
25. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit Dial Int 2001;21:158-65. (Pubitemid 32447797)